Analysts at Evercore ISI assumed coverage on shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in a research report issued to clients and investors on Monday, Marketbeat reports. The brokerage set an “outperform” rating on the specialty pharmaceutical company’s stock.

Several other analysts have also recently issued reports on ADMS. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. BidaskClub cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Cowen and Company set a $45.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Noble Financial reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $33.00 price objective (up from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $39.50.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.03 million. Adamas Pharmaceuticals’s quarterly revenue was down 90.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.78) earnings per share.

COPYRIGHT VIOLATION WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/30/adamas-pharmaceuticals-inc-adms-earns-outperform-rating-from-analysts-at-evercore-isi.html.

A number of large investors have recently added to or reduced their stakes in the stock. American International Group Inc. raised its holdings in Adamas Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after buying an additional 682 shares during the period. Alps Advisors Inc. raised its holdings in Adamas Pharmaceuticals by 6.7% during the 2nd quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock valued at $353,000 after buying an additional 1,272 shares during the period. Bank of New York Mellon Corp raised its holdings in Adamas Pharmaceuticals by 2.4% during the 1st quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock valued at $1,152,000 after buying an additional 1,563 shares during the period. Wells Fargo & Company MN raised its holdings in Adamas Pharmaceuticals by 28.4% during the 1st quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Adamas Pharmaceuticals by 4.9% during the 1st quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock valued at $2,201,000 after buying an additional 5,920 shares during the period. Institutional investors own 71.95% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.